SI1928409T1 - Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid - Google Patents

Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid

Info

Publication number
SI1928409T1
SI1928409T1 SI200631471T SI200631471T SI1928409T1 SI 1928409 T1 SI1928409 T1 SI 1928409T1 SI 200631471 T SI200631471 T SI 200631471T SI 200631471 T SI200631471 T SI 200631471T SI 1928409 T1 SI1928409 T1 SI 1928409T1
Authority
SI
Slovenia
Prior art keywords
sulfamide
pyrimidine
pharmaceutical composition
stable pharmaceutical
stable
Prior art date
Application number
SI200631471T
Other languages
English (en)
Slovenian (sl)
Inventor
Charles Tokunbo Adesuyi
Lovelace Holman
Olivier Lambert
Bruce Hamilton Lithgow
Original Assignee
Actelion Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37865339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1928409(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.
Publication of SI1928409T1 publication Critical patent/SI1928409T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200631471T 2005-09-12 2006-09-11 Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid SI1928409T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2005009775 2005-09-12
PCT/IB2006/053210 WO2007031933A2 (en) 2005-09-12 2006-09-11 Stable pharmaceutical composition comprising a pyrimidine-sulfamide
EP06809280A EP1928409B1 (en) 2005-09-12 2006-09-11 Stable pharmaceutical composition comprising a pyrimidine-sulfamide

Publications (1)

Publication Number Publication Date
SI1928409T1 true SI1928409T1 (sl) 2012-12-31

Family

ID=37865339

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631471T SI1928409T1 (sl) 2005-09-12 2006-09-11 Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid

Country Status (23)

Country Link
US (6) US20080233188A1 (enExample)
EP (2) EP1928409B1 (enExample)
JP (2) JP4955685B2 (enExample)
KR (1) KR101313395B1 (enExample)
CN (1) CN101262847B (enExample)
AU (1) AU2006290309B2 (enExample)
BR (1) BRPI0615898B8 (enExample)
CA (1) CA2621273C (enExample)
CY (1) CY1113395T1 (enExample)
DK (1) DK1928409T3 (enExample)
ES (1) ES2393117T3 (enExample)
HR (1) HRP20120957T1 (enExample)
IL (1) IL190072A (enExample)
MY (1) MY151003A (enExample)
NO (1) NO341325B1 (enExample)
NZ (1) NZ567188A (enExample)
PL (1) PL1928409T3 (enExample)
PT (1) PT1928409E (enExample)
RU (1) RU2424805C2 (enExample)
SI (1) SI1928409T1 (enExample)
TW (1) TWI323661B (enExample)
WO (1) WO2007031933A2 (enExample)
ZA (1) ZA200802947B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
MX2010001837A (es) * 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
RU2494736C2 (ru) 2008-02-20 2013-10-10 Актелион Фармасьютиклз Лтд Комбинация, включающая паклитаксел, для лечения рака яичников
PT2315587T (pt) * 2008-08-13 2018-01-31 Actelion Pharmaceuticals Ltd Produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
ES2543280T3 (es) * 2009-08-10 2015-08-17 Board Of Regents, The University Of Texas System Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
EP2512455B8 (en) 2009-12-18 2014-07-23 FrieslandCampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
IT1403248B1 (it) * 2010-11-12 2013-10-17 Scharper Therapeutics Srl Composizione per il trattamento di disfunzioni degli apparati fonatorio ed olfattorio
EP2670405B1 (en) 2011-02-04 2015-09-02 Actelion Pharmaceuticals Ltd. Combinations comprising macitentan for the treatment of glioblastoma multiforme
DE14721256T1 (de) * 2013-04-22 2017-03-16 Sandoz Ag Pharmazeutische zusammensetzungen mit kristallinem macitentan
MY204336A (en) 2013-06-13 2024-08-23 Akebia Therapeutics Inc Compositions and methods for treating anemia
WO2014198178A1 (zh) * 2013-06-14 2014-12-18 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
EP3169669A1 (en) * 2014-07-15 2017-05-24 OLON S.p.A. Amorphous form and new crystalline forms of macitentan
MY187276A (en) 2014-07-25 2021-09-17 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
CN105388244B (zh) * 2015-12-10 2017-03-08 合肥久诺医药科技有限公司 一种马西替坦有关物质的高效液相色谱分析方法
WO2018153925A1 (en) 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan
SI3897646T1 (sl) * 2018-12-21 2024-08-30 ACTELION PHARMACEUTICALS lTD, Makitentan za zdravljenje pljučne arterijske hipertenzije
TW202042818A (zh) * 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
HUE068647T2 (hu) 2019-05-22 2025-01-28 Wuxi Biocity Biopharmaceutics Co Ltd Pirimidin-szulfonamid vegyület kristályos formája és annak elõállítási módszere
BR112022000117A2 (pt) * 2019-07-05 2022-02-15 Tecnimede Sociedade Tecnico Medicinal Sa Composições compactadas de macitentana, métodos e usos das mesmas.
CA3158292A1 (en) 2019-11-29 2021-06-03 Alessandro MARESTA Methods of treating pulmonary arterial hypertension
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
TW202317119A (zh) * 2021-06-11 2023-05-01 瑞士商艾克泰聯製藥有限公司 用於口服投予之分散錠
US20240350414A1 (en) 2021-08-25 2024-10-24 Basf Se Direct tableting auxiliary composition
WO2023038600A1 (en) * 2021-09-07 2023-03-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A capsule formulation comprising macitentan
EP4154873A1 (en) 2021-09-22 2023-03-29 Sanovel Ilac Sanayi Ve Ticaret A.S. The tablet comprising macitentan

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH04103525A (ja) 1990-08-22 1992-04-06 Sanwa Kagaku Kenkyusho Co Ltd 難水溶性薬物の持続性製剤化方法
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
EP0627924B1 (en) 1992-10-02 2000-12-27 Genetics Institute, Inc. Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5811120A (en) 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
RU2172735C2 (ru) 1995-12-20 2001-08-27 Яманоути Фармасьютикал Ко., Лтд. Арилэтенсульфонамидные производные и фармацевтическая композиция
JPH103525A (ja) 1996-06-14 1998-01-06 Dainippon Printing Co Ltd Ｉｃカード、命令コード格納方法及び命令コード実行方法
AR017426A1 (es) 1997-12-08 2001-09-05 Smithkline Beecham Corp Sal de monoargininilo del acido (e)-3-[1-n-butil-5-[2-(2-carboxifenil)metoxi-4-clorofenil]-1h-pirazol-4-il]-2-[(5-metoxi-2,3-dihidrobenzofuran-6-il)metil]-prop-2-enoico, composicion farmaceutica que la contiene, su uso para la manufactura de un medicamento y procedimiento para su preparacion
CA2322315C (en) 1998-03-06 2008-09-16 Eurand International S.P.A. Fast disintegrating tablets
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US20040062803A1 (en) * 1999-12-22 2004-04-01 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor
EP1244657B1 (en) * 1999-12-31 2004-12-29 Encysive Pharmaceuticals Inc. Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
JP2001335469A (ja) 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
KR20030017569A (ko) 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
JP4334869B2 (ja) 2000-12-01 2009-09-30 協和発酵キリン株式会社 溶解性または経口吸収性の改善された組成物
AU3950802A (en) 2000-12-07 2002-06-18 Cv Therapeutics Inc Abca-1 elevating compounds
WO2002053557A1 (en) 2000-12-18 2002-07-11 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
FR2819720B1 (fr) 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
JP3930290B2 (ja) 2001-09-12 2007-06-13 富士フイルム株式会社 熱現像感光材料及びそれを用いた熱現像方法
KR20030041577A (ko) 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
CA2471951A1 (en) * 2002-01-07 2003-07-17 Pharmacia Corporation Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
EA008939B1 (ru) 2002-02-11 2007-10-26 Пфайзер Инк. Производные никотинамида, полезные в качестве ингибиторов pde4
EP1480679B1 (en) * 2002-02-26 2007-05-23 Astrazeneca AB Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
GB0204771D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
WO2004067008A1 (ja) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited 受容体作動薬
HRP20050675A2 (en) 2003-02-25 2005-10-31 Eli Lilly And Company Crystalline non-solavated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
US7220738B2 (en) 2003-12-10 2007-05-22 Activbiotics, Inc. Rifamycin analogs and uses thereof
US7094081B1 (en) 2005-03-24 2006-08-22 Delphi Technologies, Inc. Electrical connector assembly
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
RU2494736C2 (ru) 2008-02-20 2013-10-10 Актелион Фармасьютиклз Лтд Комбинация, включающая паклитаксел, для лечения рака яичников
PT2315587T (pt) 2008-08-13 2018-01-31 Actelion Pharmaceuticals Ltd Produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
EP2670405B1 (en) 2011-02-04 2015-09-02 Actelion Pharmaceuticals Ltd. Combinations comprising macitentan for the treatment of glioblastoma multiforme

Also Published As

Publication number Publication date
US20100004274A1 (en) 2010-01-07
PT1928409E (pt) 2012-11-27
EP1928409A2 (en) 2008-06-11
TW200803860A (en) 2008-01-16
US20080233188A1 (en) 2008-09-25
CN101262847B (zh) 2010-11-24
US8367685B2 (en) 2013-02-05
JP5054061B2 (ja) 2012-10-24
US20180263980A1 (en) 2018-09-20
AU2006290309A1 (en) 2007-03-22
US20130190336A1 (en) 2013-07-25
JP2009235073A (ja) 2009-10-15
US10117870B2 (en) 2018-11-06
CN101262847A (zh) 2008-09-10
WO2007031933A3 (en) 2007-10-18
KR20080055897A (ko) 2008-06-19
RU2424805C2 (ru) 2011-07-27
WO2007031933A2 (en) 2007-03-22
JP2009519893A (ja) 2009-05-21
US11648249B2 (en) 2023-05-16
BRPI0615898B1 (pt) 2020-02-18
JP4955685B2 (ja) 2012-06-20
BRPI0615898B8 (pt) 2021-05-25
CY1113395T1 (el) 2016-06-22
NO341325B1 (no) 2017-10-16
US20210186966A1 (en) 2021-06-24
HK1121950A1 (en) 2009-05-08
AU2006290309B2 (en) 2012-04-05
IL190072A0 (en) 2008-08-07
MY151003A (en) 2014-03-31
EP1928409B1 (en) 2012-09-12
HRP20120957T1 (hr) 2012-12-31
NO20081724L (no) 2008-04-09
US20160136163A1 (en) 2016-05-19
DK1928409T3 (da) 2012-11-05
US10946015B2 (en) 2021-03-16
EP2292209A2 (en) 2011-03-09
CA2621273A1 (en) 2007-03-22
US9265762B2 (en) 2016-02-23
CA2621273C (en) 2014-07-29
ES2393117T3 (es) 2012-12-18
BRPI0615898A2 (pt) 2011-05-31
PL1928409T3 (pl) 2013-02-28
KR101313395B1 (ko) 2013-10-02
NZ567188A (en) 2011-04-29
ZA200802947B (en) 2009-12-30
EP2292209A3 (en) 2011-05-04
IL190072A (en) 2013-08-29
RU2008113869A (ru) 2009-10-20
TWI323661B (en) 2010-04-21

Similar Documents

Publication Publication Date Title
ZA200802947B (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
GB0403247D0 (en) A pharmaceutical composition
EP1765283A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0408308D0 (en) Pharmaceutical compositions
ZA200708705B (en) Pharmaceutical composition
IL177480A0 (en) Pharmaceutical composition
IL188352A0 (en) Pharmaceutical compositions
IL187748A0 (en) Pharmaceutical compositions containing misoprostal
IL182703A0 (en) Pharmaceutical compositions comprising a camtothecin derivative
ZA200804103B (en) Pharmaceutical compositions
IL192091A0 (en) Pharmaceutical compositions
IL184631A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A Wht3a PROTEIN
HU0401177D0 (en) Pharmaceutical composition
GB2411355B (en) Pharmaceutical composition
EP1805154A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0400452D0 (en) A pharmaceutical composition
GB0522045D0 (en) Pharmaceutical compositions
GB0425255D0 (en) Pharmaceutical composition
ZA200701932B (en) Pharmaceutical composition
ZA200701931B (en) Pharmaceutical composition
EP1845944A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0407351D0 (en) Pharmaceutical compositions
GB0512246D0 (en) Novel pharmaceutical
GB0400971D0 (en) Pharmaceutical compositions
GB0522473D0 (en) A pharmaceutical formulation